Conversation with Robert Hankin

[vc_row][vc_column][vc_column_text]

In that capacity he has overseen the development of HIBCC from its’ early formation as a bar code labeling standards group to its’ current status as a provider of internationally-accredited healthcare supply chain product and customer identification standards. HIBCC has been designated as a Unique Device Identifier (UDI) Issuing Agency for the US Food and Drug Administration (FDA) and the European Union (EU).

Dr. Hankin earned his Ph.D. in Economics from Northeastern University in Boston, Massachusetts, USA, where he specialized in the healthcare sector. Prior to being named HIBCC President, he held senior executive positions at the American Medical Association (AMA) and the American Dental Association (ADA), and served as a Managing Consultant for a Cambridge, Massachusetts, USA- based research firm.[/vc_column_text][/vc_column][/vc_row]

A Conversation with AlphaBeta’s Andrew Charlton

Andrew has senior experience in business, government and international institutions. After commencing his career with the Boston Consulting Group (BCG), he received a Doctorate and Masters in Economics from the University of Oxford, where he studied as a Rhodes Scholar. From 2008-2010, through the period of the global financial crisis, he served as senior economic advisor to the Prime Minister of Australia and Australia’s senior government official to the G20 economic summits. He was the prime minister’s representative to conferences of the United Nations Framework Convention on Climate Change (UNFCCC) and the Major Economies Forum on Energy and Climate (MEF). From 2010-2014 he worked for Australian conglomerate Wesfarmers, including two years in corporate strategy (M&A and major group projects) and two years in operational roles (divisional Chief Financial Officer and General Manager).

Andrew’s academic research covering international economics, trade and development has been published in leading international journals including the American Economic Review, World Trade Review and World Economy. He is the author of two books, Ozonomics (2007) and Fair Trade for All (2005), co-written with Nobel laureate Joseph Stiglitz. In 2011 he was named a Young Global Leader by the World Economic Forum.

A Conversation with Stryker’s Kevin Lobo

[vc_row][vc_column][vc_column_text]

ABOUT KEVIN LOBO

Kevin A. Lobo has been CEO of Stryker since October 1, 2012, and also assumed the role of Chairman of the Board on July 22, 2014. Mr. Lobo joined Stryker in 2011 and had previously been Group President of Orthopaedics.

Mr. Lobo is the chairman of the Advanced Medical Technology Association (AdvaMed) Board of Directors and serves on the Board of Directors for Parker Hannifin Corporation, the global leader in motion and control technologies. He is also a member of the Business Roundtable and Business Council and serves on some community boards.

Mr. Lobo has a broad business career that includes executive positions in general management and finance. After holding finance positions with KPMG, Unilever and Kraft Canada he spent eight years with Rhone-Poulenc, including roles based in Europeas Corporate Controller of Rhodia, the chemical spin-out, and General Manager of Specialty Phosphates EMEA. He then spent eight years at Johnson & Johnson, including President J&J Medical Canada and President of Ethicon Endo Surgery.[/vc_column_text][/vc_column][/vc_row]

MedTech Innovator Asia Pacific

MedTech Innovator is the medical technology industry’s global showcase and accelerator for innovative medical device, digital health and diagnostic companies. Its mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. MedTech Innovator is the largest platform of its kind, providing participants with broad exposure to the leading players in the medtech industry. To accelerate innovation in Asia, we have partnered with the Asia Pacific Medical Technology Association (APACMed 亚太医疗技术协会). APACMed is the first and only regional association to provide a unified voice for the medical technology industry in Asia.

A Conversation with Sir Andrew Dillon

[vc_row][vc_column][vc_column_text]Sir Andrew joined the NHS in 1975 and has held a number of senior management positions, including General Manager of the Royal Free Hospital and Chief Executive of St George’s Healthcare NHS Trust. He joined the National Institute for Health and Care Excellence as its founding Chief Executive in 1999.[/vc_column_text][vc_separator][vc_column_text]

Question 1 : What is NICE and your role?

 

Question 2: What is health technology assessment (HTA)?

 

Question 3: What are the processes that a medical device could go through when being assessed by NICE?

 

Question 4: Has the availability of clinical data for the evaluation of medical devices been a challenge and if so, what has been the approach?

 

Question 5: What role do medical device registries play in the ongoing evaluation of the cost effectiveness of devices?

 

Question 6: What does value-based health care mean to you?

 

Question 7: How can the medical device industry become a better participant with HTA when moving into assessment?

 

Question 8: What have been the challenges to reimbursement in HTA with software as a device?

 

Question 9: How can the medical device industry help with challenges in the uptake of good cost-effective technologies?

 

[/vc_column_text][/vc_column][/vc_row]